QR Code

PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease

IntroductionImmune checkpoint inhibitors (ICI) have revolutionized the treatment of many malignancies in recent years. However, immune−related adverse events (irAE) are a frequent concern in clinical practice. The safety profile of ICI for the treatment of malignancies in patients diagnosed with aut...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Lorenz Kocheise, Ignazio Piseddu, Joscha Vonderlin, Eric T. Tjwa, Gustav Buescher, Lucy Meunier, Pia Goeggelmann, Francesca Fianchi, Jérôme Dumortier, Mar Riveiro Barciela, Tom J. G. Gevers, Benedetta Terziroli Beretta-Piccoli, Maria-Carlota Londoño, Sona Frankova, Thomas Roesner, Vincent Joerg, Constantin Schmidt, Fabian Glaser, Jan P. Sutter, Thorben W. Fründt, Ansgar W. Lohse, Samuel Huber, Johann von Felden, Marcial Sebode, Kornelius Schulze
Hōputu: Artigo
Reo:Inglês
I whakaputaina: Frontiers Media S.A. 2024-01-01
Rangatū:Frontiers in Immunology
Ngā marau:
autoimmune disease (AID)
immune checkpoint inhibitors (ICI)
autoimmune liver diseases (AILD)
immune related adverse effects (irAEs)
PD-1/PD-L1 immune checkpoint inhibitors
autoimmune hepatitis (AIH)
Urunga tuihono:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1326078/full
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite